The effectiveness as well as the metabolic effects of the combination of diuretics [hydrochlorothiazide (HCT) vs indapamide (IND)] and perindopril (P) in 14 patients (7 male, 7 female) aged 37-62 years with mild idiopathic hypertension were studied. Following a 4-week washout period and a 4-week period of monotherapy with P (4 mg/daily), IND (2.5 mg/daily) or HCT (25 mg/daily) was added for 4 weeks. Selection of the diuretic agent was random. Following a 4-week wash-out period from the diuretic, in which only P was given, the alternative diuretic was administered for another period of 4 weeks. P decreased blood pressure levels significantly. However, the drug was more efficacious in patients with higher plasma renin activity (PRA). Combination treatment induced an additional decrease in the blood pressure levels, mainly in patients with lower PRA. The combination of P ؉ HCT was more effective than the combination P ؉ IND. The addition of either HCT or IND
Introduction
Angiotensin-converting enzyme (ACE) inhibitors comprise a class of antihypertensive drugs with a very low side-effect profile. 1 However, single drug therapy is effective in approximately half of hypertensive patients. In the remaining patients, a synergistic effect upon hypotensive efficacy has been observed when even small doses of diuretics are added. [2] [3] [4] [5] Even though diuretics exert adverse metabolic effects, ACE inhibitors appear to exhibit a neutral or even a beneficial effect on lipid and carbohydrate metabolism, leading to an attenuation of the biochemical sequalae commonly associated with diuretic therapy. [6] [7] [8] [9] [10] [11] However, indapamide has been reported to induce a moderate change in the serum metabolic parameters.
evoked a small but statistically significant increase in serum glucose levels while fasting as well as during the 75 g oral glucose challenge. However, insulin levels did not change significantly during the study. Small but not statistically significant changes in serum electrolytes and lipid parameters were observed during the various phases of the study, while a statistically significant increase in the serum uric acid was noticed when the combination P ؉ HCT was given.
We conclude: (1) P in small doses is an effective and safe antihypertensive agent, (2) PRA has a predictive value in determining the effectiveness of P treatment, (3) the combination of P with small doses of HCT or IND is more efficacious than P alone, (4) the combination treatment has adverse effects in the carbohydrate tolerance, while there are not significant changes in serum electrolyte and lipid parameters.
of the combination of indapamide or hydrochlorothiazide with perindopril.
Materials and methods
A total of 14 patients (7 male, 7 female) aged 37-62 years with mild to moderate primary hypertension (sitting diastolic blood pressure (BP) у95 mm Hg and р114 mm Hg) were studied. All patients had been previously identified by the investigators as requiring a drug combination to control their BP. Criteria for exclusion were significant cardiac, hepatic, renal, and thyroid diseases, diabetes mellitus, and weight in excess of 20% of ideal body weight. Patients were not given any advice on their eating, smoking, or exercise habits during the study. Administration of any previous antihypertensive medication was discontinued at least 4 weeks before the study. The study protocol was approved by the Hospital Ethics Committee and each patient gave written consent to participate in the study.
Study protocol is shown in Figure 1 . Specifically, after the 4 weeks' wash-out period, all patients were given perindropril (4 mg once daily) for 4 weeks. Taking into account that the seated diastolic BP after perindopril treatment was more than 90 mm Hg, indapamide (2.5 mg once daily) or hydrochlorothiazide (25 mg once daily) was added for 4 weeks. Selection of the diuretic agent was random. Following a 4-week wash-out period from the diuretic, in which only perindopril was given, the alternative diuretic was administered for another period of 4 weeks. At every visit (every 4 weeks) each patient's BP was measured in the right arm with a standard mercury sphygmomanometer after the patient remained seated for 10 min. Additionally, heart rate and body weight were also measured. Compliance with drug treatment was assessed in each patient by an interview and a pill count.
In all study periods venous blood was obtained after a 12 h fast for the determination of serum metabolic parameters (glucose, creatinine, uric acid, sodium, potassium, magnesium, total cholesterol, high-density lipoprotein (HDL) cholesterol, lowdensity lipoprotein (LDL) cholesterol, apolipoprotein A 1 , apolipoprotein B, and triglycerides).
At the same time, glucose tolerance tests after ingestion of 75 g of glucose was performed and samples for serum glucose and insulin were drawn at 0, and 2 h. In all patients plasma renin activity (PRA) was measured at the beginning of the study along with 24-h urine sodium excretion.
Serum creatinine was measured by the method of Jaffe, serum glucose by the hexokinase method, serum sodium and potassium by ion selective electrodes, serum magnesium by photometric colorimetric assay, serum uric acid by the uricase/PAP method, and serum insulin by the Abbott IMx insulin assay, which is a microparticle enzyme immunoassay. Serum cholesterol and triglycerides were determined by enzymatic colorimetric assay using an RA1000 analyser (Technicon Instruments, NY, USA), while HDL cholesterol was determined enzymatically in the supernatant after precipitation of other lipoproteins with dextran sulfate-magnesium. LDL cholesterol was calculated using the Friedewald formula. Serum Apo A 1 and ApoB were measured by immunonephelometry with the aid of a Beckman array analyser (Beckman Instruments, CA, USA). PRA was measured by a radioimmunoassay.
Statistical analysis
Data are presented as means ± standard deviation. Blood pressure and biochemical parameters at the end of each study period were used for statistical analysis according to that recommended by Hills and Armitage. 14 This method allows comparison of the effects of combination of perindopril either with hydrochlorothiazide or with indapamide to be adjusted for any period effects. This method also includes a test for treatment-period interaction.
Comparison of the effects of perindopril used either alone or in combination with diuretics was derived from the differences among responses for the study periods. Significance was assessed with Student's tstatistic. No carryover effect was detected for any variable measured and therefore there was no necessity to analyse any variables as a parallel study. All statistical tests were two-tailed and were interpreted at the 5% significance level.
Results
A significant decrease in the mean BP was observed after perindopril administration in the whole group of patients [from 118.9 ± 9.3 to 108.9 ± 7.9 mm Hg, mean reduction of 8.4%, P Ͻ 0.005]. Perindopril was more efficacious in patients with higher PRA, since patients with a more than 5 mm Hg decrease in mean BP (range, 5.8-10.6 mm Hg) had higher PRA compared to those with a decrease in mean BP less than 5 mm Hg (range, 0.4 -4.2 mm Hg) [2 ± 0.8 ng/ml/h vs 0.4 ± 0.5 ng/ml/h, P Ͻ 0.01]. Furthermore, there was a good correlation between PRA values and the decrease in mean BP (r = 0.42, P = 0.02). The addition of either hydrochlorothiazide or indapamide produced an additional decrease in mean BP from 108.2 ± 8 mm Hg on monotherapy to 87 ± 9 mm Hg after 4 weeks' treatment with hydrochlorothiazide (mean reduction of 14%, P Ͻ 0.005) and from 109 ± 6.8 mm Hg on monotherapy to 98.5 ± 7 mm Hg after 4 weeks' treatment with indapamide (mean reduction of 9.6%, P Ͻ 0.01). However, the perindopril + hydrochlorothiazide combination was more effective than the perindopril + indapamide combination (P Ͻ 0.05).
No significant changes in serum lipid parameters were observed after perindopril administration in the whole group of patients (mean changes of all lipid parameters Ͻ 5%, P = NS). As shown in Table  1 , both diuretics increased the total and LDL cholesterol levels moderately, though not significantly. However, there were no significant differences in the changes of all lipid parameters measured between the two combination therapies. Perindopril administration was followed by an increase in serum potassium levels (from 4.1 ± 0.2 mm Hg to 4.3 ± 0.3 mm Hg, P = 0.08). Both hydrochlorothiazide and indapamide produced a decrease in serum potassium levels to lower than pretreatment values (from 4.4 ± 0.2 mmol/L to 3.95 ± 0.2 mmol/L after hydrochlorothiazide treatment, and from 4.3 ± 0.15 mmol/L to 4 ± 0.2 mmol/L after indapamide treatment), even though the changes in serum potassium levels were only marginally statistically significant (P = 0.08 for hydrochlorothiazide and P = 0.09 for indapamide) possibly because of the relatively small number of patients studied.
An approximately 10% decrease in serum magnesium levels was found after both diuretics' administration. However, there were no significant differences in the changes of serum electrolytes between the two combination therapies (Table 2) . A significant increase in serum uric acid levels was observed after hydrochlorothiazide administration (from 5.2 ± 1.3 mg/dl to 6 ± 1.4 mg/dl, P Ͻ 0.01), while indapamide did produce a small insignificant increase in uric acid levels (from 5.3 ± 0.9 mg/dl to 5.7 ± 0.8 mg/dl, P = NS). Subsequently, the addition of hydrochlorothiazide caused a greater increase in serum uric acid levels compared to that observed after indapamide administration (P Ͻ 0.01). Perindopril treatment was not followed by any change in either fasting or 2 h postload serum glucose levels (from 96 ± 12 mg/dl to 91 ± 9 mg/dl, and from 120 ± 12 mg/dl to 118 ± 24 mg/dl, respectively) and insulin levels (from 10.2 ± 3 mU/L to 9.9 ± 4 mU/L and from 13 ± 3 mU/L to 12 ± 6 mU/L, respectively). Both diuretics increased significantly fasting and 2 h postload glucose levels (from 90 ± 11 mg/dl to 103 ± 9 mg/dl, P Ͻ 0.01 and from 115 ± 16 mg/dl to 132 ± 12 mg/dl, P Ͻ 0.01, respectively after hydrochlorothiazide administration and from 89 ± 14 mg/dl to 99 ± 12 mg/dl, P Ͻ 0.01, and from 119 ± 16 mg/dl to 132 ± 12 mg/dl, P Ͻ 0.01, respectively after indapamide administration), while there were no significant differences in the changes of carbohydrate metabolism parameters between the two combination therapies. Even though the fasting and 2 h postload serum insulin levels were somewhat increased after the addition of both diuretics, the changes were not statistically significant (Table 3) .
Discussion
Our study reconfirmed that perindopril is an effective antihypertensive drug without any adverse metabolic effects on carbohydrate or lipid metabolism. 15 In agreement with previously published data the drug's antihypertensive efficacy was related to the renin-angiotensin axis activation; that is, the BP fall was well correlated to the pretreatment PRA. 16, 17 However, a considerable proportion of hypertensive patients exhibit an inadequate response to monotherapy with ACE inhibitors, as was the case in our patients. 3, 18 In such cases, the addition of a diuretic to a standard dose of ACE inhibitor gives a better response than increasing the dose of ACE inhibitor. 4 Thus, the combination of ACE inhibitors with diuretics appears to represent an ideal choice in terms of efficacy, compliance, side effects and cost. [19] [20] [21] In fact, in our patients a near normalisation of BP values after diuretics administration was achieved. The synergistic action of ACE inhibitordiuretic combination allows the diuretic dose to be reduced, leading to a reduction in the metabolic side effects commonly observed with diuretic therapy. 8, 22, 23 Accordingly, previous studies have shown that the addition of ACE inhibitors to thiazides can blunt or even prevent the metabolic consequences of diuretic therapy, while they enhance their antihypertensive effect. [6] [7] [8] [9] [10] [11] Nonetheless, there seem to be a few studies concerning the metabolic consequences of added thiazide diuretics to ACE inhibitors. Additionally, comparison of the observed biochemical derangements between hydrochlorothiazide and indapamide when added to ACE inhibitors is lacking. This is of special importance, since indapamide is an effective and safe antihyper- tensive drug, thought to be unique among diuretics devoid of lipid or other metabolic effects. 12, 13 However, our study showed that hydrochlorothiazide at a dose of 25 mg/day was more effective than indapamide at a dose of 2.5 mg/day, when both drugs are added in patients on perindopril treatment. Thus, our results point to the suggestion that a hydrochlorothiazide dose of not less than 25 mg is necessitated to achieve optimal BP lowering. 7, 9 Nevertheless, at this dosage a number of adverse metabolic effects was observed, namely a 10% increase in serum total and LDL cholesterol levels, an increase in serum uric acid levels, and, most importantly, a significant increase in serum glucose levels. Similar changes, however, even though of lower degree, were also found after indapamide treatment, while the only significant difference between the two combination therapies concerns the increase in serum uric acid levels, which was significantly higher after hydrochlorothiazide administration. Interestingly, after both diuretics' treatment a significant increase in fasting and 2 h postload glucose levels was evident, while no significant change in both fasting and 2 h postload insulin levels was found, suggesting that diuretics could directly or indirectly (through hypokalaemia) decrease pancreatic insulin secretion. 24, 25 Even though evaluation of insulin sensitivity using the euglycaemic glucose clamp technique was not performed in our study, it is noteworthy that no beneficial effect of perindopril on serum glucose and insulin levels both fasting and 2 h postloading relative to baseline was demonstrated. Thus, the putative beneficial effect of ACE inhibitors on carbohydrate metabolism remains controversial. [26] [27] [28] [29] It is possible that the impact on sensitivity to insulin varies with different ACE inhibitors, 30 and it is dependent on the degree of underlying insulin resistance. If subjects are not particularly insulin resistant, as was the case in our patients, then it may be more difficult to reveal a beneficial effect. 26 Furthermore, the ACE inhibitor dosage could have also played a role in its influence in the carbohydrate tolerance, since in one study the administration of only high doses of captopril (Ͼ100 mg/day) mitigated the hyperglycaemic effect of hydrochlorothiazide. 6 Therefore, a placebo-controlled study to address the effect of ACE inhibition on sensitivity to insulin in essential hypertension needs to be carried out.
A small increase in serum potassium levels was observed after perindopril therapy and a decrease to lower than pretreatment values followed the two combination therapies. Nevertheless, the 25 mg of hydrochlorothiazide did not induce a significant decrease in serum potassium levels to hypokalaemic levels, suggesting that perindopril guards against the hypokalaemic effects of the added diuretics. The changes in potassium homeostasis could have played a role in the diuretic-induced adverse effects on carbohydrate metabolism. It has been suggested that the decrease in serum potassium levels might impair insulin secretion and inhibit muscle glucogen synthase activity, which is associated with a decrease in insulin-mediated uptake of glucose. 24, 31 Our data clearly showed that the administration of ACE inhibitor did not ameliorate the adverse effects of diuretics in agreement with recently published data, which reported that combination therapy evoked hepatic insulin resistance when 5 mg of bendrofluazide was used. 26 Consequently, great care needs to be exercised in the use of these combinations notwithstanding that they are particularly efficacious in lowering BP, as it is also illustrated in the present study. It should be mentioned that it is not certain what the effects of ACE inhibitors combined with lower doses of hydrochlorothiazide will be. This is of special importance, since many of the combined proprietary preparations of ACE inhibitors and thiazides available in Europe contain smaller quantities of thiazide diuretics compared to those used in this study.
